Eluciderm

Phase I/IIA open-label case study clinical trial evaluating the safety and effectiveness of ELU42, a small molecule wnt signaling modulator, in the treatment of diabetic foot ulcers.

Criteria:

• Type 1 or 2 diabetic
• Chronic non-healing wound on the foot
• Wound not infected or ischemic
• Willing to attend 3x weekly visits for 12 weeks total, with treatments for 6 weeks